Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
11:07am, Thursday, 14'th May 2026
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
Aquestive Therapeutics Q1 Earnings Call Highlights
10:09am, Thursday, 14'th May 2026
Aquestive Therapeutics NASDAQ: AQST said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter of 2
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
07:00pm, Wednesday, 13'th May 2026
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key me
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates
06:15pm, Wednesday, 13'th May 2026
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.24 per share a year ago.
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
04:01pm, Wednesday, 13'th May 2026
WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
09:31am, Tuesday, 12'th May 2026
WARREN, N. J. , May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvemen
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
09:31am, Tuesday, 12'th May 2026
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful impr
WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful impr
NEW YORK--(BUSINESS WIRE)---- $AQST #AQST--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (“Aquestive” or the
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Monday, 04'th May 2026
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive
New York, New York--(Newsfile Corp. - May 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between Jun
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know
11:06am, Monday, 04'th May 2026
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options If you purchased or acquir
AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
06:30pm, Sunday, 03'rd May 2026
NEW YORK, May 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Sunday, 03'rd May 2026
New York, New York--(Newsfile Corp. - May 3, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
